Results of special studies with alendronate.
Major Phase III studies were planned to address basic issues regarding the effectiveness and safety of alendronate. However, 3 special studies were designed to provide information regarding the effectiveness and safety of alendronate therapy for postmenopausal osteoporosis that complement the result of the large Phase III osteoporosis trials, addressing the duration of the drug's antiresorptive effect after withdrawal of therapy, the effects of alendronate therapy in more elderly subjects and a comparison of alendronate with another treatment for osteoporosis.
McClung
M
M
Department of Medical Education, Providence Portland Medical Center and Oregon Osteoporosis Center, Portland, Oregon, USA.
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016896:Treatment Outcome
D002116:Calcitonin; D019386:Alendronate